Teva’s Partner Antares Swallowed Up By Halozyme In $960m Deal
Teva/Antares Alliance Offers Gx EpiPen; US Forteo Rival Under Development
Executive Summary
For just shy of $1bn, Halozyme Therapeutics is set to acquire drug development and injectable technology specialist Antares Pharma, providing it with a portfolio and pipeline of Teva products through a long-term partnership.
You may also be interested in...
Sun’s Teriparatide And Multiple Aubagio Rivals Among CHMP Recommendations
Sun’s rival to Forsteo, Accord and Mylan’s versions of Aubagio and Accord’s Nexavar generic were all endorsed by the European Medicines Agency at the CHMP’s September meeting.
Amphastar’s Forteo ANDA Hit With CRL As Wait Goes On
Amphastar will not be receiving approval in 2022 for its proposed generic version of Eli Lilly’s Forteo (teriparatide) peptide for the treatment of osteoporosis, after the FDA told the company it could not issue an approval at this stage.
Teva Identifies Teriparatide Importance Amid US Launch Drought
Teva acknowledged that it was “not independent of the macro environment in the US,” as it saw another significant drop off for its North America generics business amid a lack of new launches. The Israeli giant took the unusual step of singling out a complex generic asset – its proposed generic to Eli Lilly’s Forteo – as “the most important” potential launch for its 2022 top line.